CD105和细胞周期蛋白D1协同表达与食管鳞癌淋巴结转移及预后的关系

目的 探讨食管鳞癌中CD105和细胞周期蛋白D1(cyclin D1)的协同表达与淋巴结转移和预后的关系.方法 应用免疫组织化学方法检测南通市第一人民医院收治的80例食管鳞癌患者食管鳞癌组织中CD105和cyclin D1的表达,分析两者协同表达与食管鳞癌淋巴结转移及预后的关系.选取80例正常食管组织作对照.采用方差分析或t检验、x2检验、Pearson相关分析,生存分析采用Kaplan-Meier法,CD105的表达用微血管密度(MVD)值以-x±s表示.结果 食管鳞癌组织和正常食管组织CD105表达分别为36±8和11±3;Cyclin D1阳性表达率分别为61%(49/80)和23%(18/80),两者比较,差异有统计学意义(t=25.129,x2=4.972,P<0.05).按照食管鳞癌中CD105标记的MVD均值36为界,分为LCD105(MVD≤36)和HCD105(MVD＞36),其中LCD 44例,HCD 36例.LCD105淋巴结转移9例,HCD淋巴结转移26例.Cyclin D1阳性表达者有淋巴结转移28例,阴性表达者淋巴结转移7例.经Pearson列联相关分析显示CD105高表达、cyclin D1阳性表达与淋巴结转移有关(x2=21.562,9.217,P<0.05).HCD105+cyclin D1阳性28例,生存时间为(31±6)个月;LCD105+cyclin D1阳性21例,生存时间为(47±7)个月;HCD105+cyclin D1阴性8例,生存时间为(51±9)个月;LCD105+cyclin D1阴性23例,生存时间为(61±5)个月,4者比较,差异有统计学意义(F=11.76,P<0.05).结论 CD105和cyclin D1两者协同表达可作为判断食管鳞癌预后的指标.

Relationship between the co-expression of CD105 and cyclin D1 and lymph node metastasis and prognosis of esophageal squamous cell carcinoma

Objective To investigate the relationship between the co-expression of CD105 and cyclin D1 and lymph node metastasis and prognosis of esophageal squamous cell carcinoma ( ESCC ). Methods Eighty cases of ESCC tissue were collected at The First People's Hospital of Nantong. The expression of CD105 and cyclin D1 of ESCC was detected by immunohistochemistry. The relationship between the co-expression of CD105 and cyclin D1 and lymph node metastasis and prognosis of ESCC was analysed. Eighty normal esophageal tissues were selected as controls. All data were analysed by t test, chi-square test, and Pearson correlation analysis. Survival was analysed by the Kaplan-Meier survival curve. Microvessel density (MVD) was used to indicate the expression of CD105 in the form of -x±s. Results The expression of CD105 in ESCC tissues was higher (36±8) than that in normal esophageal tissues ( 11±3) (t =25. 129, P＜0.05). The positive rate of cyclin D1 expression in ESCC tissues was 61% (49/80), which was significantly higher than 23% (18/80) in normal esophageal tissues ( x2 =4.972, P＜0.05). The MVD value of 44 patients was ≤36 (LCD105), and nine of them had lymph node metastasis. The MVD value of the remaining 36 patient was ＞ 36 ( HCD105 ), and 26 of them had lymph node metastasis. Twenty-eight patients with positive expression of cyclin D1 had lymph node metastasis, while seven patients with negative expression of cyclin D1 had lymph node metastasis. The results of Pearson correlation analysis revealed that a high expression of CD105 and a positive cyclin D1 expression were correlated with lymph node metastasis (x2 =21.562, 9.217, P＜0.05). The survival times of 28 patients with positive cyclin D1 and HCD105,21 patients with positive cyclin D1 and LCD105, eight patients with negative cyclin D1 and HCD105, and 23 patients with negative cyclin D1 and LCD105 were (31±6) months, (47±7) months, (51±9) months and (61±5) months, respectively, with a significant difference among the four groups (F = 11.76, P ＜ 0. 05 ).Conclusion Co-expression of CD105 and cyclin D1 may be used as a prognostic factor of ESCC.